Cytokinetics offers asymmetric commercial-transition upside as MYQORZO challenges Camzyos and expands into nHCM, but LVEF safety and cash-burn risks make execution decisive.
Overview
Cytokinetics is transitioning from a clinical-stage muscle-biology company into a commercial specialty cardiovascular enterprise anchored by MYQORZO (aficamten), approved in the U.S., EU, Great Britain, and China for symptomatic oHCM. Its short approximately 3.5-day half-life, rapid titration, and minimal drug interactions differentiate it from BMS’s Camzyos, enabling more than 40% new-to-brand CMI share within five months of U.S. launch. **Commercial traction is visible but earnings remain far away**: Q2 2026 revenue was $28.624 million, including $25.334 million of MYQORZO sales, while the company posted a $198.762 million GAAP loss and spent $207.796 million on operating expenses. Cash and short-term investments reached $1.704 billion after a $760.1 million equity raise, but first-half operating burn was $305.3 million. **The principal catalyst is nHCM expansion**, with an sNDA planned for Q4 2026 and a MAPLE-HCM PDUFA date of November 14, 2026. The report’s $105.42 probability-weighted target versus $72.09 current price reflects substantial upside, but depends on safety, reimbursement, launch execution, and pipeline delivery.